Anaspec now provides a Clearpoint B-Amyloid custom peptide synthesis service.
Clearpoint peptides make up the company's trademark collection of heavy or stable isotope-labelled peptides and amino acids.
Clearpoint peptides offer a choice of heavy carbon (13C) or nitrogen (15N) isotopes specifically labelled at single or universal positions.
These peptides can be used for the quantitative analyses of B-Amyloid peptides in biological fluids using mass spectrometry (MS).
The inclusion of internal heavy isotope-labelled peptide standards makes MS an absolute quantitation (AQUA) method for the peptide of interest.
B-Amyloid (1-40) and (1-42) peptides have been used as biomarkers of Alzheimer's disease (AD).
Historically, ELISA assays have been used in the quantitation of these peptides.
However, technical challenges such as the tendency of B-Amyloid (1-40 and 1-42) peptides to self aggregate, undergo post-translational modifications or bind to other proteins often result in inaccuracies in quantitation when using ELISA.
